If Glaukos sat on your watchlist instead of in your account, the move over the last 12 months may feel like a missed call. For Glaukos shareholders, the return over the past year was 89.3%, including dividends. That kind of outcome invites a harder question. Back on 5 October 2025, could an investor reasonably spot that confidence in iDose TR and a broader ocular therapy portfolio might be the key business swing factor to watch?
A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.
This theme extends beyond Glaukos. See which of 33 healthcare AI stocks may still merit a closer look.
The Argument Glaukos Investors Were Really Weighing
The shares cost US$87.41 at the start, and Glaukos sat between two very different but believable stories about where its ocular therapies could lead.
On the optimistic side, the bullish Narrative set Fair Value at US$123, 40% above the start price. It leaned on strong adoption of iDose TR as evidence that interventional glaucoma treatments could reshape how glaucoma is treated globally.
The more cautious view put Fair Value at US$74.28 and focused on reimbursement cuts and tougher competition. In that scenario, revenue growth assumptions were capped at 21.6% and profit margins were limited to 5.9%.
What The Evidence Did To The Glaukos Argument
Glaukos reported Q2 2026 revenue of US$185.61 million, above US$124.12 million a year earlier, and management lifted 2026 sales guidance after strong iDose TR and Epioxa demand. That reinforced the optimistic case that product adoption would matter more than reimbursement worries. Yet the group still reported a loss of US$18.38 million and a net margin of 9.9% in decline.
The lesson for readers is simple. When a story hinges on product uptake and margin improvement, keep checking reported segment sales and net margin, not just guidance or commentary about addressable markets.
What Glaukos Buyers Are Being Asked To Believe Now
Glaukos now trades at US$164, after an 89.3% gain over the past year, and the selected Narrative’s Fair Value sits above that level on its own assumptions.
The Narrative leans on stronger uptake of iDose TR, Epioxa and a broadening ophthalmic portfolio. It claims today’s price still does not fully credit the impact of faster adoption in minimally invasive eye procedures.
"While the analyst consensus expects gradual iDose TR uptake as reimbursement solidifies, current surging adoption rates in MAC regions with established professional fees suggest the addressable market is significantly understated, with the possibility for far faster nationwide physician training and utilization once all MACs align, pointing to outsized revenue acceleration sooner than expected."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Glaukos And A Different Kind Of Tool
Glaukos lives in eye care, but your watchlist does not need to stop there.
If you like the idea of procedures becoming less invasive, look one step sideways to another business building robotic tools for surgeons.
Its systems turn complex operations into screen-guided work with finely controlled instruments and tailored training.
Surgeons get data and feedback wrapped around the hardware so they can refine technique.
As hospitals lean into gentler surgery, that kind of platform could quietly shape how care is delivered.
It is written up in full, assumptions and all. → Explore the Narrative that puts this company 31% above its price
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com